<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04266314</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00190055</org_study_id>
    <nct_id>NCT04266314</nct_id>
  </id_info>
  <brief_title>Maternal Marijuana Use and Fetal and Infant Outcome</brief_title>
  <official_title>Maternal Marijuana Use and Fetal and Infant Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Marijuana and cannabis-containing products are growing in popularity and availability in the
      United States, and use during pregnancy has increased dramatically. The overarching aim of
      this proposal is to provide pilot data for a submission which will explore the impact of
      chronic maternal marijuana use (primary or secondary) on fetal functioning, maternal
      reflective functioning and infant birth and neurodevelopmental outcomes. Chronically
      marijuana using pregnant women in treatment at the Center for Addiction and Pregnancy will be
      enrolled and asked to provide information about participants' marijuana and other licit and
      illicit substance use and feelings about parenting and participants' infant and undergo fetal
      monitoring at 36 weeks gestation. The neonates will undergo neurobehavioral examination
      during the first and fourth weeks of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">April 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Prevalence of maternal cannabis use disorder</measure>
    <time_frame>The first day of study enrollment and again at infant delivery</time_frame>
    <description>Rates of Cannabis use disorder among pregnant women reporting primary or secondary (i.e. first or second drug of choice) cannabis use during pregnancy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fetal functioning as assessed by fetal heart rate</measure>
    <time_frame>One day during 36th weeks of gestation</time_frame>
    <description>Fetal heart rate in beats per minute will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fetal functioning as assessed by fetal movement</measure>
    <time_frame>One day during 36th weeks of gestation</time_frame>
    <description>Fetal movement: number and length in msecs of bouts of fetal movement as determined by fetal actograph testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in infant neurobehavioral functioning as assessed by the NICU Network Neurobehavioral Scale</measure>
    <time_frame>One day during week 1 and week 4 of infant life</time_frame>
    <description>Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Maternal reflective functioning as assessed by the Parental Reflective Functioning Questionnaire</measure>
    <time_frame>At 36 weeks of gestation, postpartum week 1, postpartum week 4</time_frame>
    <description>Responses that evaluate the mother's ability to reflect on and interpret her own behavior and that of her child in terms of mental states and intentions; this will be assessed using the Parental Reflective Functioning Questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant weight at birth</measure>
    <time_frame>At the time of delivery</time_frame>
    <description>Birth weight in kilograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant length at birth</measure>
    <time_frame>At the time of delivery</time_frame>
    <description>Infant length in centimeters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant head circumference at birth</measure>
    <time_frame>At the time of delivery</time_frame>
    <description>Infant head circumference in centimeters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant Apgar Score at 1 minute</measure>
    <time_frame>At 1 minute after delivery</time_frame>
    <description>Apgar Score after birth at one minute; scores range from 1-10 with higher scores signifying more optimal infant well being at birth.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant Apgar Score at 5 minutes</measure>
    <time_frame>At 5 minutes after delivery</time_frame>
    <description>Apgar Score after birth at five minutes; scores range from 1-10 with higher scores signifying more optimal infant well being at birth.</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cannabis Use Disorder</condition>
  <condition>Pregnancy Related</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Maternal-fetal monitoring</intervention_name>
    <description>Maternal-fetal monitoring evaluates fetal and maternal heart rate, maternal respirations, fetal movement, and maternal skin conductance (a way to monitor emotional response)</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NICU Network Neurobehavioral Scale</intervention_name>
    <description>Evaluates neurobehavioral organization, neurological reflexes, motor development, and signs of stress and withdrawal of substance-exposed infants.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronically marijuana using women enrolled at the Center for Addiction and Pregnancy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Maternal Inclusion Criteria:

          -  Singleton pregnancy less than 36 weeks of gestation

          -  Marijuana as a primary or secondary drug of choice

        Maternal Exclusion Criteria:

          -  Significant fetal anomaly

          -  Multiple gestation

          -  Delivery prior to 36 weeks gestation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Jansson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krystle McConnell, MPH</last_name>
    <phone>410-550-8779</phone>
    <email>kgreen39@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Jansson, MD</last_name>
    <phone>410-550-5438</phone>
    <email>ljansson@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystle McConnell, MPH</last_name>
      <phone>410-550-8779</phone>
      <email>kgreen39@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Jansson, MD</last_name>
      <phone>410-550-8779</phone>
      <email>ljansson@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Martha Velez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauren Jansson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krystle McConnell, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nancy Spencer, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pajulo M, Tolvanen M, Karlsson L, Halme-Chowdhury E, Ã–st C, Luyten P, Mayes L, Karlsson H. THE PRENATAL PARENTAL REFLECTIVE FUNCTIONING QUESTIONNAIRE: EXPLORING FACTOR STRUCTURE AND CONSTRUCT VALIDITY OF A NEW MEASURE IN THE FINN BRAIN BIRTH COHORT PILOT STUDY. Infant Ment Health J. 2015 Jul-Aug;36(4):399-414. doi: 10.1002/imhj.21523. Epub 2015 Jun 19.</citation>
    <PMID>26096692</PMID>
  </reference>
  <reference>
    <citation>Lester BM, Andreozzi-Fontaine L, Tronick E, Bigsby R. Assessment and evaluation of the high risk neonate: the NICU Network Neurobehavioral Scale. J Vis Exp. 2014 Aug 25;(90). doi: 10.3791/3368.</citation>
    <PMID>25177897</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cannabis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Marijuana Use</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

